Skip to main content

Targeting AML

By Gwen Nichols, M.D., LLS Chief Medical Officer | May 16, 2017

 

Not for lack of trying, we’ve seen very little progress over the past 40 years in treating acute myeloid leukemia (AML), an aggressive and deadly blood cancer. But we’re finally starting to see the needle move and The Leukemia & Lymphoma Society (LLS) is playing a leading role in going on the offensive against the disease.